 |
|
|
|
 |
|
|
| Article 1 to 5 out of 5 concerning Novartis Pharma AG
|
-
ACZ885, a new biological drug in development, shows potential in treating serious life-long autoinflammatory diseases
(10 Apr 2008)
Human monoclonal antibody ACZ885 blocks interleukin 1ß, a key chemical messenger that causes inflammation and tissue destruction
New data demonstrate that ACZ885, a human monoclonal antibody in Phase III development, achieves long-lasting clinical remission in patients with genetic autoinflammatory diseases. The results indicate that ACZ885 could develop into a major ...
-
Novartis: Eucreas recommended for EU approval for type 2 diabetes
(25 Sep 2007)
Novartis has received a positive opinion recommending European Union approval for Eucreas®, an oral tablet combining Galvus® (vildagliptin) and metformin, as a new treatment for patients with type 2 diabetes. Following approval, Eucreas will be the ...
-
Phosphagenics and Nestlé Nutrition extend option agreement
(10 Jul 2007)
Phospha E® clinical program to progress as planned
Phosphagenics Limited announced that it has, by mutual consent, extended the period in which a commercial agreement is to be concluded with Nestlé Nutrition. In January 2007, Nestlé exercised its option to negotiate (on an exclusive basis) a ...
-
"Memory" of nicotine lingers in the brain, say Scripps Research Scientists
(04 Oct 2005)
Persistence May Have Implications for Kicking the Smoking Habit
Scientists at The Scripps Research Institute and Scripps Florida are reporting the results of one of the first studies looking at the long-term neurological effects of nicotine addiction on the brain's reward system. Their findings may have ...
-
Novartis: PTK/ZK CONFIRM 1 Study Shows Positive Drug Effects in Phase III Study in Metastatic Colorectal Cancer
(22 Mar 2005)
Novartis Pharma AG and Schering AG announced that the analysis of progression free survival (PFS) as assessed by central radiology review in the CONFIRM 1 trial with the investigational drug PTK/ZK did not achieve statistical significance. However, ...
|
|
|
|
|
Top
